IKONISYS overview

Regulatory News: ALIKO SCIENTIFIC (Ikonisys SA) (Euronext Growth Paris: ALIKO) , announces that its Italian subsidiary Hospitex International has launched Urine24.com , the first online-available urinary cytology test for early bladder cancer diagnosis. The service is now available through its official website offering a non-invasive, fast, and highly reliable solution for millions of Italians. Urine24 to Address a Critical Need in the Italian Market In Italy, bladder cancer is one of the most...

Regulatory News: Hospitex, the Italian leader in the production of Cytology medical devices and fully owned subsidiary of ALIKO SCIENTIFIC (Ikonisys SA) (Euronext Growth Paris: ALIKO ), a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories, has secured a prestigious public tender from the Ecclesiastical Entity F. Miulli Regional General Hospital. This contract marks a significant milestone in the...

Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO) , a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories (the “ Issuer ”), today announces the completion of a capital increase of €500k by way of a private placement with a specialized investor. This transaction is part of the Company strategy to strengthen its net financial position while expanding its shareholder base with specialized...

Regulatory News: ALIKO SCIENTIFIC (Ikonisys SA) (Euronext Growth Paris: ALIKO) , today announces that its subsidiary Hospitex, the Italian leader in the production of medical devices, has secured a major contract to supply IT and networking systems for hospitals in Adwa, Ethiopia. The initial step, estimated to nearly €300k, is part of a broader project funded by the United Nations (UNOPS) and marks a major milestone for the newly established Hospitex Digital division , which is dedicated to...

Regulatory News: Ikonisys Inc., a leader in advanced cell-based diagnostic solutions fully owned by ALIKO SCIENTIFIC (Ikonisys SA) (Euronext Growth Paris: ALIKO), is proud to announce the grant of a new U.S. patent by the United States Patent and Trademark Office (USPTO) entitled “Automated Fluorescence Microscopy Method to Determine the Efficacy of Cancer and Hyperplasia Treatments” . Commercially known as “ACTA Technology” (Automated Cancer Treatment Assessment) , this milestone...

Regulatory News: Hospitex, the Italian leader in the production of medical devices and a subsidiary of ALIKO SCIENTIFIC (Ikonisys SA) (Euronext Growth Paris: ALIKO), today announces that it has secured a public tender for the Azienda Ospedaliera Universitaria "Gaetano Martino" in Messina, Italy. The contract, valued at €668 thousand over three years, includes an option to extend it for two additional years, bringing the total potential value to €1.025 million . The tender covers the supply...

Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO) , a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories (the “ Issuer ”), today announces a capital increase of 300k€ through the offsetting of debt owed to Cambria KOP BV, a Dutch investment company, and the emission of 196,080 shares of the Company. This operation strengthens the Company's net financial position and broadens its...

Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO) , a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories (the “ Issuer ”), today announces that it has completed the acquisition of Hospitex International Srl, with the issuance of 2 million new Ikonisys shares to ETH Scientific Srl, the former owner of Hospitex. As disclosed in November 2023, Ikonisys signed an agreement to buy 100% of...